This month the West Midlands set out its reindustrialisation blueprint at the Growth Summit in Coventry, in the same week a new Scale-up Pathway linked the WestTech London cluster with the region's manufacturing strength. An announcement is only the start of the work, and the question that matters is who carries an innovation across the final mile, from a good idea to a safe, repeatable, everyday reality.

This month the West Midlands set out a clear ambition. At the Growth Summit in Coventry on 8 October, the West Midlands Combined Authority published its reindustrialisation blueprint. In the same week came a new Scale-up Pathway, convened by Imperial College London and the University of Warwick, linking the WestTech London innovation cluster with the industrial strength of the Midlands.

 

The framing is striking. HS2 is described not as a commuter line but as an innovation line, connecting Old Oak in London with Arden Cross in the West Midlands. The idea is simple to say and hard to do. Bring research and investment strength together with engineering, manufacturing and supply chains, so that more British ideas are made and grown in Britain.

The numbers give it weight. The West Midlands produces over £22 billion of manufacturing output each year. The WestTech London cluster brings together around a thousand frontier companies. Since 2020, the Warwick Innovation District reports supporting around 4,000 founders and helping raise more than £200 million. These figures come from the partners' own announcements, and they describe scale that is already here, not a promise.

We welcome this. It matters that national attention is moving further north, and that the West Midlands is being recognised as a place where things are designed, made and scaled. But an announcement is the start of the work, not the end of it. The question that decides whether any of this lands is an old one: who actually carries an innovation across the final mile, from a good idea to a safe, repeatable, everyday reality?

The final mile is where innovation is won or lost

VeinTrain works at that final mile. We are a specialist provider of IV cannulation, venepuncture and phlebotomy training, built on real clinical teaching and structured learning. Our interest in reindustrialisation is practical, not abstract.

Part of what we do is practical UK production. Our thinking on the final mile of innovation grew out of building UK-based production capability for VeinTrain's training products, including a 20,000-unit production run. A device is only useful if it can be produced at volume, supplied reliably and used correctly by the people who need it. The design is the easy part. The supply chain, the training and the governance around it are the hard part. That is where most promising ideas quietly stall.

A walkthrough of a UK production run, filmed by Sarah Phillips (86 seconds). Watch on Vimeo.

We see the same thing in workforce capability. A new technique, device or product only improves patient care when a clinician can use it safely, under local supervision, within their scope of practice. That is a translation problem as much as a technical one. It needs teaching, structured learning, and a clear line between training completion and local competency sign-off. A certificate can evidence learning. It does not replace an employer's competency assurance. Safe scale depends on respecting that distinction.

Regional capability, not London by another name

The most important word in this announcement may be "regional". For years, "innovation ecosystem" has too often meant London. Moving capability north, and connecting it rather than centralising it, is the right instinct. But regional capability is not only large institutions and large numbers. It is also the small businesses, the local manufacturers and the practical operators who turn plans into production.

This is familiar ground for us in the East Midlands. VeinTrain is a member of the Rushcliffe Business Partnership, and we have arranged a Midlands production visit with our local MP's office to see British manufacturing at work. Small businesses do not usually reach an innovation ecosystem through a summit. They reach it through supply contracts, shared facilities, local networks and practical support. A pathway succeeds when it reaches them, not only when it is launched by others.

That is a systems point as much as an economic one. The conditions for collaboration do not appear because a strategy is announced. They are built. They depend on trust across organisational boundaries, on relationships between research, industry and public services, and on someone taking responsibility for the unglamorous work of making things fit together. Leadership across those boundaries is the quiet infrastructure of any ecosystem. Without it, even well-funded initiatives struggle to move from research to reality.

What we will be watching

Three things will tell us whether this pathway delivers.

  1. Whether it keeps manufacturing capability in the UK in practice, not just in language.
  2. Whether small and mid-sized businesses can genuinely get in, or whether the benefits pool around the largest players.
  3. Whether the route from research to implementation is actually resourced, because the final mile is always underfunded relative to the headline.

We are optimistic, and we intend to play our part. We can move fast, but we move safely. That is how safe scale works in real services and fragile systems, where the cost of getting it wrong is carried by patients.

If the West Midlands pathway treats the final mile as the main event rather than an afterthought, it has a real chance of turning regional ambition into national capability. That is worth celebrating, and worth working for.

If you are working on regional workforce capability, distributed training, or translating a clinical innovation into safe practice at scale, reply or book a short conversation. We would be glad to talk about workforce rollout, HALO Training Centres or partnership in the Midlands and beyond.

Sources